Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14679417 | 0.96 | NPC1 (0.58) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24061105 | 0.92 | FYN (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11996634 | 0.91 | NPC1 (0.62) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14679386 | 0.86 | NPC1 (0.64) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9492626 | 0.86 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18773534 | 0.85 | SMN1; SMN2 (0.60) | MEN1KMT2ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL24061104 | 0.85 | FYN (0.59) | MEN1KMT2ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL24061011 | 0.85 | PTAFR (0.59) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL7055005 | 0.85 | NPC1 (0.62) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1909677 | 0.84 | KDM4E (0.55) | MEN1KMT2ASMN1; SMN2HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011882-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| US-9169246-B2 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-10-27 | — | — | US | disclosed |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| EP-2448914-A1 | CONTINUOUS METHOD FOR PRODUCING AMIDES OF AROMATIC CARBOXYLIC ACIDS | Clariant Finance (BVI) Limited (VG) | 2012-05-09 | — | — | EP | disclosed |
| US-20120095238-A1 | Continuous Method For Producing Amides Of Aromatic Carboxylic Acids | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-04-19 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| WO-2011000459-A1 | CONTINUOUS METHOD FOR PRODUCING AMIDES OF AROMATIC CARBOXYLIC ACIDS | CLARIANT INTERNATIONAL LTD (CH) | 2011-01-06 | — | — | WO | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, COQ8A, CYP1A2 | NPC1 365/4885RAB9A 855/4885MEN1 1323/4885 |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, CYP1A2, COQ8A | NPC1 418/4885RAB9A 813/4885MEN1 1372/4885 |
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | NPC1 743/4885RAB9A 3196/4885MEN1 2597/4885 |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | NPC1 714/4885RAB9A 331/4885MEN1 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.